a-ra-f

alpha-RA-F can modulate collagen synthesis and matrix metalloproteinases (MMPs) expression levels by boosting collagen synthesis and reducing MMPs expression levels in human fibroblasts without cytotoxicity.

Sulfo-ara-F-NMN is an analogue of nicotinamide mononucleotide (NMN) with cellular permeability. Sulfo-ara-F-NMN was selective to activate SARM1 and inhibited CD38 with an IC50 of about 10 μM. Activation by Sulfo-ara-F-NMN to Z-48 or NMN, which has a higher cyclase activity, causes conformational changes in SARM1, resulting in cADPR production, NAD depletion, and non-apoptotic cell death.

Sarafloxacin hydrochloride (A-56620 (hydrochloride)), a quinolone antibiotic drug, is a hydrochloride salt form of sarafloxacin.

Chlorzoxazone (Chlorzoxazon) is a Muscle Relaxant. The physiologic effect of chlorzoxazone is by means of Centrally-mediated Muscle Relaxation.

LXH254 is a B/C RAF inhibitor with IC50 values of 0.2 nM and 0.07 nM for inhibiting BRAF and CRAF.

Tarafenacin D-tartrate (SVT-40776 D-tartrate) is a selective and potent muscarinic acetylcholine M3 receptor antagonist used in the study of overactive bladder and bronchial disorders.

Tarafenacin is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over the M2 receptor.

Para-fluoro methylaminorex is a neuroactive compound.

Des-ethyl-carafiban (Compound 44) is an antagonist of the fibrinogen receptor, effectively inhibiting platelet aggregation induced by various agonists. It is useful for research in thrombotic diseases.

Sarafloxacin (A56620) has antibacterial activities against Gram-positive and Gram-negative bacteria.

Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant respectively.

Paraflutizide is a thiazide analog antihypertensive.

Ara-fluorocytosine is a biochemical.

Ara-F-NAD+, an arabino analogue of NAD + , is a potent, slow-binding CD38 NADase inhibitor, with a K i of 169 nM.

Belvarafenib (HM95573) is a potent pan-RAF inhibitor with antitumor activity and inhibits B-RAF, B-RAFv600E, and C-RAF with IC50 values of 56, 7, and 5 nM.

Uplarafenib (B-Raf IN 10) is a potent BRAF inhibitor with an IC50 of 50-100 nM. B-Raf IN 10 exhibits antitumor activity that may influence cell proliferation and differentiation, making it suitable for studying solid tumors.

Exarafenib (RAF/KIN_2787) is a potent, orally available pan-RAF inhibitor with antitumor activity that acts by inhibiting downstream MAPK pathway signaling. It is used in cancer research.

Belvarafenib TFA (HM95573 TFA) is a potent and broadly available inhibitor of fibrosarcoma kinase (RAF), acting on B-RAF (IC50: 56 nM), B-RAFv600E (IC50: 7 nM), and C-RAF (IC50: 5 nM).

Paraffin liquid is a useful organic compound for research related to life sciences and the catalog number is T64746.

Ara-F-NAD+ sodium, an arabino analogue of NAD+, serves as a potent, reversible, and slow-binding inhibitor of the CD38 NADase [1] [2].

Sarafotoxin S6a TFA, an analogue of sarafotoxin, functions as an endothelin receptor agonist with an ET_A/ET_B selectivity profile akin to Endothelin-3. It demonstrates an EC_50 of 7.5 nM in stimulating the pig coronary artery [1].

[Lys4] Sarafotoxin S6c, an analogue of sarafotoxin, serves as a potent, partial agonist of the endothelin receptor, inducing contraction in pig coronary artery with an effective concentration (EC 50) of 1.5 nM [1].

Tagarafdeg (CFT1946) is an orally available PROTAC degradator targeting mutant BRAF, capable of degrading BRAF V600E (Class I), G469A (Class II), G466V (type III) mutations, and the p61-BRAF V600E splice variant. It exhibits favourable selectivity within the proteome, including for wild-type BRAF and CRAF, and inhibits tumour cell proliferation.

Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2 is a biologically active peptide functioning as a selective agonist for Protease Activated Receptor 1 (PAR-1) [a subtype of G-protein coupled receptors involved in mediating thrombin's cellular effects]. Exhibiting high specificity for PAR-1 over PAR-2, its selectivity was assessed via cell-based calcium signaling assays in HEK293 cells. As an agonist, it is instrumental for in vivo investigations of PAR-1 activation. PAR-1 also collaborates with PAR-4, influencing thrombin-induced hepatocellular carcinoma within [coagulation type] tumor environments where thrombin generation occurs.